Search Result
Results for "
fat accumulation
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-134577
-
|
Adrenergic Receptor
|
Endocrinology
|
Clorprenaline is a potent agonist of β2-adrenergic. Clorprenaline promotes animal muscular mass growth and decreases fat accumulation. Clorprenaline is a potential new lean meat-boosting feed additive .
|
-
-
- HY-N7515
-
2',4',6'-Trihydroxychalcone
|
Bacterial
AMPK
|
Infection
Metabolic Disease
Inflammation/Immunology
|
Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .
|
-
-
- HY-P5275
-
CG-Lipoxyn
|
NF-κB
|
Metabolic Disease
|
Tripeptide-41(CG-Lipoxyn)isa bioactive peptide withreduce fat accumulationeffect and has been reported used as a cosmetic ingredient .
|
-
-
- HY-N14035
-
|
ATP Citrate Lyase
|
Cardiovascular Disease
Metabolic Disease
|
Garcinia cambogia extract contains several active compounds, including hydroxycitric acid (HCA) (an ECC inhibitor), xanthones, benzophenones, hydroxycitric acid (an ATP-citrate lyase inhibitor). Garcinia cambogia extract lowers the body weight gain, visceral fat accumulation, blood and hepatic lipid concentrations, and plasma insulin and leptin levels in a high-fat diet (HFD)-induced obesity mouse model. Garcinia cambogia extract is promising for research of fatty liver, dyslipidemia, hyperinsulinemia and hyperleptinemia rendered by HFD .
|
-
-
- HY-N10755
-
|
PGE synthase
|
Metabolic Disease
Inflammation/Immunology
|
(+)-ε-Viniferin is a stilbenes compound with PGE2 inhibition effect, and is an orally active anti-inflammatory agent. ε-viniferin is also able to reduce fat accumulation, thus can be used for research of inflammation or obesity .
|
-
-
- HY-134577R
-
|
Reference Standards
Adrenergic Receptor
|
Endocrinology
|
Clorprenaline (Standard) is the analytical standard of Clorprenaline. This product is intended for research and analytical applications. Clorprenaline is a potent agonist of β2-adrenergic. Clorprenaline promotes animal muscular mass growth and decreases fat accumulation. Clorprenaline is a potential new lean meat-boosting feed additive .
|
-
-
- HY-13766
-
VX-853
|
PPAR
|
Others
|
Timcodar is a macrolide agent, and studies have shown that during adipogenesis, timcodar can significantly inhibit fat accumulation, with an effect similar to that of rapamycin. However, unlike rapamycin, timcodar does not cause immunosuppression and glucose resistance. In addition, timcodar can effectively inhibit the adipogenic transcriptional regulators PPAR?? and C/EBP??, thereby inhibiting genes involved in fat accumulation. These studies lay the foundation for timcodar as a potential anti-obesity therapy, as obesity is becoming a global epidemic.
|
-
-
- HY-118634
-
R-4G
|
FATP
|
Metabolic Disease
|
Trans-Resveratrol-4'-O-D-Glucuronide (R-4G) is a metabolite of resveratrol with anti-fat accumulation property, and can be used for metabolic research .
|
-
-
- HY-128135
-
|
PPAR
|
Inflammation/Immunology
|
MHY 553 is a PPARα agonist that is effective when taken orally. MHY 553 helps alleviate liver fat accumulation by increasing fatty acid oxidation and reducing inflammation during the aging process. MHY 553 inhibits the accumulation of triglycerides induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly suppresses the expression of inflammatory mRNA in aging rats .
|
-
-
- HY-161985
-
|
PPAR
|
Metabolic Disease
|
PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .
|
-
-
- HY-115319
-
|
Ferroptosis
|
Inflammation/Immunology
|
CP-24879 (hydrochloride) is a potent, selective and combined delta5D/delta6D inhibitor. CP-24879 (hydrochloride) can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 (hydrochloride) exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes, and can be used for non-alcoholic steatohepatitis research .
|
-
-
- HY-133180
-
|
Wnt
β-catenin
|
Metabolic Disease
|
YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .
|
-
-
- HY-N13248
-
|
Glycosidase
|
Metabolic Disease
|
Mulberry Leaf Extract is a mulberry leaf extract, and its components include: 1-Deoxynojirimycin. Mulberry Leaf Extract can effectively alleviate the adverse effects of high-fat diet on blood lipids and renal function, regulate lipid metabolism abnormalities, and significantly inhibit the accumulation of glycosylated substances in glomeruli. Mulberry Leaf Extract can regulate the key signaling pathways of diabetic nephropathy, but does not directly affect blood glucose levels. .
|
-
-
- HY-W127409
-
|
Biochemical Assay Reagents
|
Others
|
1,2-Dimyristoyl-rac-glycerol (C14:0) is a carboxylic acid ester, glycerolipid and diglyceride with an additional myristoyl group that facilitates interactions between proteins and lipids. Can be used as detergent or reagent. It plays a role in cell biology experiments involving the metabolism and metabolic pathways of glycerolipids. As a diglyceride, this substance consists of two fatty acid chains covalently bonded in the 1,2-form to a glycerol molecule. The diglyceride (DAG) study investigated the process by which DAG is depleted to inhibit fat accumulation. Reagent grade, for research use only.
|
-
-
- HY-171069
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
FFA2 agonist-1 (Compound 4) is the agonist for Free fatty acid receptor 2 (FFA2/GPR43) with an EC50 of 81 nM. FFA2 agonist-1 exhibits activity in β-arrestin-2 recruitment assay and cAMP inhibition assay with EC50 of 1.2 μM and 0.53 μM. FFA2 agonist-1 leads to appetite regulating
peptide YY (PYY) mucosal responses, inhibits the fat accumulation, intestinal functions and food intake, and can be used for obesity research .
|
-
-
- HY-W018791
-
DDB
|
HBV
Autophagy
Cytochrome P450
Atg8/LC3
p62
P-glycoprotein
|
Infection
Cardiovascular Disease
Cancer
|
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .
|
-
-
- HY-N8518
-
|
Phospholipase
p38 MAPK
Apoptosis
NF-κB
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .
|
-
-
- HY-W015924
-
|
Endogenous Metabolite
|
Metabolic Disease
|
2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
|
-
-
- HY-W015924R
-
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
2-Hydroxyisobutyric acid (Standard) is the analytical standard of 2-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
|
-
-
- HY-10585B
-
VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)
|
HDAC
Autophagy
Mitophagy
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
-
-
- HY-10585
-
-
-
- HY-10585A
-
Sodium Valproate sodium
|
Organoid
HDAC
Autophagy
Mitophagy
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
-
-
- HY-10585AR
-
Sodium Valproate sodium (Standard)
|
Organoid
Reference Standards
HDAC
Autophagy
Mitophagy
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
-
-
- HY-10585AG
-
Sodium Valproate (sodium)
|
Organoid
HDAC
Autophagy
Mitophagy
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
-
-
- HY-N0322B
-
|
Liposome
Endogenous Metabolite
|
Others
|
Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity.
In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloid protein and enhances the secretion of Aβ1-40 in HEK cells transfected with APP .
In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol . Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation . Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-10585AG
-
Sodium Valproate (sodium) (GMP)
|
Fluorescent Dye
|
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
Cat. No. |
Product Name |
Type |
-
- HY-W127409
-
|
Drug Delivery
|
1,2-Dimyristoyl-rac-glycerol (C14:0) is a carboxylic acid ester, glycerolipid and diglyceride with an additional myristoyl group that facilitates interactions between proteins and lipids. Can be used as detergent or reagent. It plays a role in cell biology experiments involving the metabolism and metabolic pathways of glycerolipids. As a diglyceride, this substance consists of two fatty acid chains covalently bonded in the 1,2-form to a glycerol molecule. The diglyceride (DAG) study investigated the process by which DAG is depleted to inhibit fat accumulation. Reagent grade, for research use only.
|
-
- HY-10585AG
-
Sodium Valproate (sodium) (GMP)
|
Biochemical Assay Reagents
|
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5275
-
CG-Lipoxyn
|
NF-κB
|
Metabolic Disease
|
Tripeptide-41(CG-Lipoxyn)isa bioactive peptide withreduce fat accumulationeffect and has been reported used as a cosmetic ingredient .
|
-
- HY-125357
-
|
Peptides
|
Metabolic Disease
|
Ternatin (compound 2) is a cyclic heptapeptides that can be isolated from mushroom Coliorus versicolor. Ternatin inhibits fat-accumulation with an IC50 of 0.027 μM in 3T3-L1 adipocytes .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N7515
-
-
-
- HY-N14035
-
|
Structural Classification
Natural Products
Guttiferae
Source classification
Garcinia cambogia Desr.
Plants
|
ATP Citrate Lyase
|
Garcinia cambogia extract contains several active compounds, including hydroxycitric acid (HCA) (an ECC inhibitor), xanthones, benzophenones, hydroxycitric acid (an ATP-citrate lyase inhibitor). Garcinia cambogia extract lowers the body weight gain, visceral fat accumulation, blood and hepatic lipid concentrations, and plasma insulin and leptin levels in a high-fat diet (HFD)-induced obesity mouse model. Garcinia cambogia extract is promising for research of fatty liver, dyslipidemia, hyperinsulinemia and hyperleptinemia rendered by HFD .
|
-
-
- HY-N8518
-
-
-
- HY-W015924
-
-
-
- HY-10585
-
-
-
- HY-10585A
-
-
-
- HY-N10755
-
-
-
- HY-W015924R
-
|
Structural Classification
Ketones, Aldehydes, Acids
Source classification
Endogenous metabolite
|
Reference Standards
Endogenous Metabolite
|
2-Hydroxyisobutyric acid (Standard) is the analytical standard of 2-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
|
-
-
- HY-10585B
-
-
-
- HY-10585AR
-
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-N0322B
-
|
|
Emulsifiers
Liposomal Film-forming Agents
|
Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity.
In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloid protein and enhances the secretion of Aβ1-40 in HEK cells transfected with APP .
In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol . Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation . Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: